Working… Menu

Trial of CMB305 and Atezolizumab in Patients With Sarcoma (IMDZ-C232)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02609984
Recruitment Status : Completed
First Posted : November 20, 2015
Last Update Posted : May 20, 2019
Genentech, Inc.
Information provided by (Responsible Party):
Immune Design

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : March 29, 2019
Actual Study Completion Date : March 29, 2019